期刊
EXPERIMENTAL GERONTOLOGY
卷 44, 期 6-7, 页码 372-374出版社
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.exger.2009.04.001
关键词
GH; IGF-1; Aging; Frailty; Mutants
资金
- NIA (NIH) [AG19899, U19 AG023122]
- Ellison Medical Foundation
- Glenn Foundation
Reduced somatotropic (GH/IGF-1) signaling delays aging and extends longevity in laboratory mice. However, it is unclear whether the physiological decrease of GH and IGF-1 levels with age represents a symptom of declining neuroendocrine function, a cause of age-related alterations in body composition and functionality or a protective mechanism against age-associated disease. Although available clinical evidence does not support the use of recombinant GH as an anti-aging therapy, many studies suggest the potential utility of GH and GH secretagogues in the treatment of sarcopenia and frailty. (C) 2009 Published by Elsevier Inc.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据